What is the CHADS2 (Congestive heart failure, Hypertension, Age ≥ 75 years, Diabetes, Stroke or transient ischemic attack) scoring system?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 23, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The CHADS2 score is a widely used tool to assess stroke risk in patients with atrial fibrillation, assigning points for congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, and prior stroke or TIA. The CHADS2 score is calculated as follows:

  • C - Congestive heart failure (1 point)
  • H - Hypertension (1 point)
  • A - Age ≥75 years (1 point)
  • D - Diabetes mellitus (1 point)
  • S2 - Prior Stroke or TIA (2 points) The total score ranges from 0-6, with higher scores indicating greater stroke risk, as supported by studies such as 1 and 1. This score helps clinicians determine whether anticoagulation therapy is necessary, with patients having a score of 0 considered low risk, 1 as moderate risk, and 2 or higher as high risk, often warranting anticoagulation, as recommended by guidelines such as 1 and 1. Some key points to consider when using the CHADS2 score include:
  • The score has been validated in multiple studies, including 1 and 1
  • The score is simple and easy to use in clinical practice
  • Newer scores, such as CHA2DS2-VASc, offer more refined risk stratification, as discussed in 1 and 1
  • The threshold for anticoagulation therapy may vary depending on individual patient factors, such as bleeding risk and patient preferences, as noted in 1 and 1. Overall, the CHADS2 score remains a valuable tool for assessing stroke risk in patients with atrial fibrillation, and its use can help guide clinical decision-making regarding anticoagulation therapy, as supported by the evidence from 1, 1, and 1.

From the Research

Overview of the CHADS2 Scoring System

The CHADS2 scoring system is a clinical prediction rule used to estimate the risk of stroke in patients with nonvalvular atrial fibrillation, as well as in other patient populations 2, 3, 4, 5, 6.

Components of the CHADS2 Score

The CHADS2 score is calculated based on the presence or absence of the following conditions:

  • Congestive heart failure
  • Hypertension
  • Age ≥ 75 years
  • Diabetes
  • Stroke or transient ischemic attack (doubled)

Calculation of the CHADS2 Score

Each condition is assigned a point value, with the exception of stroke or transient ischemic attack, which is assigned 2 points. The total score ranges from 0 to 6 points.

Clinical Applications of the CHADS2 Score

The CHADS2 score has been used to predict the risk of stroke in various patient populations, including:

  • Patients with nonvalvular atrial fibrillation 2, 3, 5, 6
  • Hypertensive patients without known atrial fibrillation 2
  • Patients without atrial fibrillation 4
  • Patients with atrial fibrillation who undergo percutaneous coronary revascularization 5

Predictive Value of the CHADS2 Score

Studies have shown that the CHADS2 score is a useful predictor of stroke risk, with higher scores indicating a greater risk of stroke 2, 3, 4, 5, 6. The score has also been shown to predict poor neurological outcome and long-term mortality in patients with atrial fibrillation-related ischemic stroke 6.

Key Findings

  • The CHADS2 score is a proven tool for estimating cardioembolic risk in patients with nonvalvular atrial fibrillation 2
  • The score may be useful for estimating the risk of stroke or transient ischemic attack in hypertensive patients without known atrial fibrillation 2
  • The CHADS2 score has a relatively high performance for stroke prediction in individuals without atrial fibrillation 4
  • A high-risk CHADS2 score is an independent predictor of poor neurological outcome and long-term mortality in patients with atrial fibrillation-related ischemic stroke 6

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.